Clinical Trial News & Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
First Patient Dosed in Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer
AUSTIN, Texas, May 14, 2024. Genprex, Inc. ("Genprex" or the "Company"), a clinical-stage gene therapy company focused on developing life-changing therapies...
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
SHANGHAI, May 13, 2024, Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its...
Geisinger enrolls first patient in amyloid cardiomyopathy trial
DANVILLE, Pa., May 10, 2024. Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac...
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J.--(BUSINESS WIRE) May 13, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of...
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology...
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--May 8, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and...
Bayer to Unveil Late-Breaking Data from Phase III OASIS 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause
Berlin, May 8, 2024 – 08 May 2024 -- Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and...
Faster Approach for Starting Extended-Release Naltrexone to Treat Opioid Use Disorder Shown Effective
May 8, 2024 -- Starting people with opioid use disorder on extended-release, injectable naltrexone (XR-naltrexone) within five to seven days of seeking...
Positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
STOCKHOLM, May 6, 2024. Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead...
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of Duravyu in Non-Proliferative Diabetic Retinopathy
WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
SEATTLE and VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company...
NRx Pharmaceuticals Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
RADNOR, Pa., May 6, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical...
Phase 2 data for Erleada plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer results published
SAN ANTONIO, May 3, 2024. Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with...
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage...
Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism
Lyon, France, and Cambridge, MA, May 2, 2024 — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and...
Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder
NEW YORK, May 1, 2024. Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for...
Scientists Discover How an Essential Nutrient Enters the Brain
May 1, 2024 -- Researchers have discovered that choline, an essential nutrient vital for brain health, is actively transported from the bloodstream into the...
NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
RADNOR, Pa., April 30, 2024, NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company today that its...
Ingenium Therapeutics Novel NK Cell Therapy IGNK001 Receives Orphan Drug Designation From FDA
DAEJEON, Korea, April 30, 2024 /PRNewswire/ -- Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its...
Clinical trial results archive
- 2024
- January, February, March, April, May
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.